protein

Mouse Vascular Endothelial Growth Factor 164AA Recombinant

MBS553124

0.01 mg

220 USD

Recombinant Protein

Mouse Vascular Endothelial Growth Factor 164AA Recombinant

Vascular Endothelial Growth Factor 164AA

vegf; vascular endothelial

vascular endothelial growth factor A isoform 1; Vascular endothelial growth factor A; Vascular permeability factor

VEGF

Vegfa; Vegf; VEGF-A; VPF

VEGFA_MOUSE

E Coli

392

MNFLLSWVHW TLALLLYLHH AKWSQAAPTT EGEQKSHEVI KFMDVYQRSY CRPIETLVDI FQEYPDEIEY IFKPSCVPLM RCAGCCNDEA LECVPTSESN ITMQIMRIKP HQSQHIGEMS FLQHSRCECR PKKDRTKPEN HCEPCSERRK HLFVQDPQTC KCSCKNTDSR CKARQLELNE RTCRCDKPRR

>95%, as determined by SDS-PAGE and HPLC

Recombinant mouse VEGF was lyophilized from 0.2 um filtered PBS solution, pH 7.0.

The lyophilized protein is stable for at least 2 years from date of receipt at -20 degree C. Upon reconstitution, this cytokine can be stored in working aliquots at 2 degree - 8 degree C for one month, or at -20 degree C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.

Domain: cystine knot growth factor. Host Note: Optimized DNA sequence encoding Mouse Vascular Endothelial Growth Factor mature chain was expressed in Escherichia Coli.

Endotoxin: Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/ug (1EU/ug). Reconstitution: A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers. Molecular Weight Note: Native mouse VEGF-164 is generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately 14 kDa. Recombinant Vascular endothelial growth factor is a disulfide-linked homodimer protein consisting of 165 amino acid residue subunits, and migrates as an approximately 28 kDa protein under non-reducing and as 14kDa under reducing conditions in SDS-PAGE.

Cytokines

VEGF is a homodimeric heavily glycosylated protein.The human factor occurs in several molecular variants of 121, 162, 145, 148, 165, 183, 189, 206 amino acids, arising by alternative splicing of the mRNA.The splice forms of VEGF differ in biological properties such as the receptor types, which they recognize and their interaction with heparan sulfate proteoglycans. The 165 amino acid form of the factor is the most common form in most tissues. Kaposi sarcomas express VEGF121 and VEGF165. VEGF121 and VEGF165 are soluble secreted forms of the factor while VEGF189 and VEGF206 are mostly bound to heparin-containing proteoglycans in the cell surface or in the basement membrane. A high-affinity glycoprotein receptor of 170-235 kDa is expressed on vascular endothelial cells. The interaction of VEGF with heparin-like molecules of the extracellular matrix is required for efficient receptor binding. Protamine sulfate and suramin are capable of replacing the receptor-bound factor. The high-affinity receptor for VEGF, now known as VEGFR1, has been identified as the gene product of the FLT-1. Another receptor for VEGF, now known as VEGFR2, is KDR, also known as FLK-1. A factor that competes with the 165 amino acid form of VEGF for receptor binding is PLGF. A third receptor type, VEGFR3 is known also as FLT- 4. An isoform-specific receptor for VEGF165 has been identified as human Neuropilin-1.

decreased nephrin and glepp-1, but increased VEGF , flt-1, and nitrotyrosine, expressions in kidney tissue sections from women with preeclampsia . Reproductive Sciences, Oct 2009; 16: 970 - 979. significantly higher levels of vascular endothelial growth factor ( VEGF ) and shorter survival times for patients with primary operable triple-negative breast cancer . Ann. Onc., Oct 2009; 20: 1639 - 1646. comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF -mediated angiogenesis and upa-mediated invasion . Am. J. Pathol., Oct 2009; 175: 1638 - 1652. autocrine loop between vascular endothelial growth factor ( VEGF ) -c and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells . Am. J. Pathol., Oct 2009; 175: 1709 - 1721. polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (poems) syndrome refractory to complete serum vascular endothelial growth factor ( VEGF ) blockade: insights from sequential VEGF monitoring . NDT Plus, Oct 2009; 2: 357 - 359.

160358799

NP_001020421.2

NM_001025250.3

Q00731

25,283 Da

Bladder Cancer Pathway 83308!!Bladder Cancer Pathway 527!!Cytokine-cytokine Receptor Interaction Pathway 83248!!Cytokine-cytokine Receptor Interaction Pathway 460!!Endochondral Ossification Pathway 198336!!Focal Adhesion Pathway 198353!!Focal Adhesion Pathway 83264!!Focal Adhesion Pathway 478!!Formation Of Platelet Plug Pathway 366293!!Hemostasis Pathway 366292

Function: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. May play a role in increasing vascular permeability during lactation, when increased transport of molecules from the blood is required for efficient milk protein synthesis . By similarity. Subunit structure: Homodimer; disulfide-linked. Also found as heterodimer with PGF . By similarity. Subcellular location: Isoform VEGF-1: Secreted. Isoform VEGF-2: Secreted. Isoform VEGF-3: Cell membrane; Peripheral membrane protein. Note: Remains cell-surface associated unless released by heparin. Tissue specificity: In developing embryos, expressed mainly in the choroid plexus, paraventricular neuroepithelium, placenta and kidney glomeruli. Also found in bronchial epithelium, adrenal gland and in seminiferous tubules of testis. High expression of VEGF continues in kidney glomeruli and choroid plexus in adults. Developmental stage: Levels increase during pregnancy (maximum 5.5-fold at 5 days) and a more marked increase occurs during lactation (maximal 9.7-fold at 7 days). Levels decrease progressively during the phase of involution. Ref.9. Induction: By IL-6 and FSH in vitro. Ref.10. Domain: Isoform VEGF-3 contains a basic insert which acts as a cell retention signal. Sequence similarities: Belongs to the PDGF/VEGF growth factor family. Sequence caution: The sequence AAH61468.1 differs from that shown. Reason: Erroneous initiation.

0.01 mg

220 USD